Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $37.66 USD
Change Today +0.08 / 0.21%
Volume 119.6K
CSII On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

cardiovascular systems inc (CSII) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $39.68
52 Week Low
10/1/14 - $23.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cardiovascular systems inc (CSII) Related Bloomberg News

View More Bloomberg News

cardiovascular systems inc (CSII) Related Businessweek News

No Related Businessweek News Found

cardiovascular systems inc (CSII) Details

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products include catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The company markets its products through direct sales force to hospitals and office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

479 Employees
Last Reported Date: 08/28/14
Founded in 1989

cardiovascular systems inc (CSII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $330.7K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $305.4K
Chief Healthcare Policy Officer
Total Annual Compensation: $318.7K
Chief Administrative Officer, Compliance Offi...
Total Annual Compensation: $296.4K
Compensation as of Fiscal Year 2014.

cardiovascular systems inc (CSII) Key Developments

Cardiovascular Systems Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 10:15 AM

Cardiovascular Systems Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 10:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: David L. Martin, Chief Executive Officer, President and Director.

Cardiovascular Systems Inc. Appoints William E. Cohn as Class III Director and Member of the Governance/Nominating Committee

On February 27, 2015, the Board of Directors of Cardiovascular Systems Inc. approved an increase in the number of directors from seven to eight and elected Dr. William E. Cohn as a Class III director. The Board of Directors also appointed Dr. Cohn as a member of the Governance/Nominating Committee.

Cardiovascular Systems Inc. to Present Orbit II Two-Year Coronary Data at 2015 Cardiovascular Research Technologies Conference

Cardiovascular Systems Inc. will release two-year data from its ORBIT II study of the company’s Diamondback 360® Coronary Orbital Atherectomy System (OAS) in treating severely calcified lesions at the 2015 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 21-24, 2015. The pivotal ORBIT II study evaluated the safety and effectiveness of the company’s orbital atherectomy technology, and CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012. In October 2013, the company received PMA approval from the U.S. Food and Drug Administration to market its Diamondback 360 Coronary Orbital Atherectomy System as a treatment for severely calcified coronary arteries. It is estimated that significant arterial calcium is present in nearly 40% of patients treated with interventional therapies. Calcium can cause complications, including difficult stent deployment, dissections and, when stents are under expanded, it can result in the need for a coronary bypass. Since receiving approval, CSI has continued the controlled commercial launch of its Diamondback Coronary Orbital Atherectomy System (OAS) in the United States and more than 4,000 patients have been treated using CSI’s unique technology.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSII:US $37.66 USD +0.08

CSII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.61 USD +0.05
Avinger Inc $10.98 USD -0.04
CryoLife Inc $10.07 USD +0.09
LeMaitre Vascular Inc $8.33 USD +0.08
Spectranetics Corp/The $34.79 USD +0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation CSII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOVASCULAR SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at